Bruce C Galton from Madison, NJ, age 72

Principal

view source

Location:

8 Holden Ln, Madison, NJ 07940

Industry:

Biotechnology

Work:

Galton Consulting
Principal
Infusion Pharma Consulting Llc 2012 - 2018
Senior Advisor
Arroyo Biosciences 2012 - 2018
Acting Chief Executive Officer
Chrysalis Pharma Partners 2009 - 2012
Managing Director
Senesco Technologies 2001 - 2009
Chief Executive Officer

Education:

University of Virginia 1970 - 1974
Bachelors, Bachelor of Science, Commerce

Skills:

Due Diligence
Healthcare Consulting
Business Strategy
Strategic Planning
Technology Transfer
Project Management
Intellectual Property
P&L Management
Start Ups Management
Alliance Negotiation
Start Ups
Business Development
Strategy
Entrepreneurship
Biotechnology
Management
Commercialization

Bruce Galton

view source

Us Patents

Sirna Useful To Supress Expression Of Eif-5A1
view source
US Patent:

8242256, Aug 14, 2012
Filed:

Dec 17, 2009
Appl. No.:

12/640148
Inventors:

John E. Thompson - Waterloo, CA
Bruce C. Galton - Madison NJ, US
Catherine Taylor - Waterloo, CA
Adrienne Boone - Waterloo, CA
Elizabeth Heikkila - Waterloo, CA
Dominic Cliche - Kitchner, CA
Shelley Culp-Stewart - Brandford, CA
John Gerard Flanagan - Waterloo, CA
Michelle Senchyna - Fort Worth TX, US
Assignee:

Senesco Technologies, Inc. - New Brunswick NJ
International Classification:

C07H 21/04
US Classification:

536 245
Abstract:

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.

Inhibition Of Apoptosis-Specific Eif-5A ("Eif-5A1") With Antisense Oligonucleotides And Sirna As Anti-Inflammatory Therapeutics
view source
US Patent:

20060094677, May 4, 2006
Filed:

May 23, 2005
Appl. No.:

11/134445
Inventors:

John Thompson - Waterloo, CA
Bruce Galton - Madison NJ, US
Catherine Taylor - Waterloo, CA
Charles Dinarello - Boulder CO, US
Leonid Reznikov - Aurora CO, US
Adrienne Boone - Waterloo, CA
Marianne Hopkins - New Hamburg, CA
International Classification:

A61K 48/00
C07H 21/04
C07H 21/02
C12N 15/85
US Classification:

514044000, 435455000, 536023100
Abstract:

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFKB by inhibiting expression of apoptosis-specific eIF-5A.

Use Of Apoptosis-Specific Eif-5A Sirnas And Antisense Polynucleotides To Inhibit/Suppress An Inflammatory Response
view source
US Patent:

20060154887, Jul 13, 2006
Filed:

Jul 20, 2005
Appl. No.:

11/184982
Inventors:

John Thompson - Waterloo, CA
Bruce Galton - Madison NJ, US
Catherine Taylor - Waterloo, CA
Charles Dinarello - Boulder CO, US
Leonid Reznikov - Aurora CO, US
Adrienne Boone - Waterloo, CA
Marianne Hopkins - Kitchener, CA
International Classification:

A61K 48/00
C07H 21/02
C12N 15/87
US Classification:

514044000, 435455000, 536023100
Abstract:

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.

Use Of Antisense Oligonucleotides Or Sirna To Suppress Expression Of Eif-5A1
view source
US Patent:

20060178330, Aug 10, 2006
Filed:

Nov 28, 2005
Appl. No.:

11/287460
Inventors:

John Thompson - Waterloo, CA
Bruce Galton - Madison NJ, US
Catherine Taylor - Waterloo, CA
Adrienne Boone - Waterloo, CA
Elizabeth Helkkila - Waterloo, CA
Dominic Cliche - Marieville, CA
Shelley Culp-Stewart - Brantford, CA
John Flanagan - Waterloo, CA
Michelle Senchyna - Fort Worth TX, US
Assignee:

Senesco Technologies, Inc. - New Brunswick NJ
International Classification:

A61K 48/00
C07H 21/02
US Classification:

514044000, 536023100
Abstract:

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.

Apoptosis-Specific Eif-5A And Polynucleotides Encoding Same
view source
US Patent:

20060287265, Dec 21, 2006
Filed:

Dec 5, 2005
Appl. No.:

11/293391
Inventors:

John Thompson - Waterloo, CA
Bruce Galton - Madison NJ, US
Catherine Taylor - Waterloo, CA
Charles Dinarello - Boulder CO, US
Leonid Reznikov - Aurora CO, US
Adrienne Boone - Waterloo, CA
Marianne Hopkins - Kitchener, CA
International Classification:

A61K 48/00
C12N 15/09
US Classification:

514044000, 435455000
Abstract:

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for increasing or decreasing expression of apoptosis-specific eIF-5A. The invention also relates to methods of increasing or decreasing apoptosis.

Inhibition Of Apoptosis-Specific Eif-5A(Elf-5A1") With Antisense Oligonucleotides And Sirna As Anti-Inflammatory Therapeutics
view source
US Patent:

20120129910, May 24, 2012
Filed:

May 2, 2011
Appl. No.:

13/099171
Inventors:

John E. Thompson - Waterloo, CA
Bruce C. Galton - Madison NJ, US
Catherine Taylor - Waterloo, CA
Charles Dinarello - Boulder CO, US
Leonid Reznikov - Aurora CO, US
Adrienne Boone - Waterloo, CA
Marianne Hopkins - New Hamburg, CA
Assignee:

Senesco Technologies Inc. - New Brunswick NJ
International Classification:

A61K 31/713
C12N 5/071
C07H 21/02
US Classification:

514 44 A, 536 245, 435377
Abstract:

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines or inhibiting activation of NFkB by inhibiting expression of apoptosis-specific eIF-5A.

Use Of Antisense Oligonucleotides Or Sirna To Suppress Expression Of Eif-5A1
view source
US Patent:

20130066058, Mar 14, 2013
Filed:

Aug 10, 2012
Appl. No.:

13/572123
Inventors:

John E. Thompson - Waterloo, CA
Bruce C. Galton - Madison NJ, US
Catherine Taylor - Waterloo, CA
Adrienne Boone - Waterloo, CA
Elizabeth Margaret Heikkila - Waterloo, CA
Dominic Cliche - Marieville, CA
Shelley Culp-Stewart - Brantford, CA
John Gerard Flannagan - Waterloo, CA
Michelle Senchyna - Fort Worth TX, US
International Classification:

C12N 15/113
US Classification:

536 245
Abstract:

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.